Glenmark will be responsible for manufacturing and supplying Ryaltris while Lotus will commercialize the drug in the targeted markets. In lieu of this, Glenmark will receive an upfront payment as well as regulatory and sales-based payments from Lotus.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
Business Wire India Ekata, a global leader in digital identity verification, today expanded its account opening solutions to help online businesses worldwide quickly identify and flag risky account sign-ups. Powered by a proprietary data set and machine learning, Ekata’s account opening solutions assess the risk of new accounts in real-time, enabling businesses to create streamlined onboarding experiences for legitimate customers and reject or add friction […]
The company’s revenue from operations rose 59.3% yoy to Rs21.12cr in Q3FY22.
Record date for dividend is 25 January 2022
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
